For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Ac Immune Sa

Calculating rank

USPTO Granted Patents = 69

% Expired Patents = 5.8

CIPO Patents = 7

EPO Patents = 44

Trademarks = 3

Forward Citations = 307

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Andreas Muhs (33 out of 34 patents)

Andrea M Pfeifer (26 out of 36 patents)

Oskar Adolfsson (18 out of 18 patents)

4. Maria Pihlgren (17 out of 17 patents)

5. David T Hickman (13 out of 13 patents)

6. Ryan Jefferson Watts (10 out of 39 patents)

7. Isidro Hotzel (9 out of 18 patents)

8. Maria Pihlgren Bosch (9 out of 9 patents)

9. Heiko Kroth (8 out of 9 patents)

10. Marija Vukicevic Verhille (7 out of 7 patents)

11. Emanuele Gabellieri (7 out of 9 patents)

12. Gai Ayalon (7 out of 8 patents)

13. Danielle Marie Di Cara (7 out of 7 patents)

14. Wolfgang Froestl (6 out of 11 patents)

15. Fred Van Leuven (6 out of 7 patents)

Core Competencies:

Anti-Tau Antibodies

Tau Peptide Vaccine

Amyloid-Beta

Therapeutic Vaccines

Diagnostic Compounds

Humanized Antibodies

Neurofibrillary Tangles

Phosphospecific Antibodies

Supramolecular Constructs

Bicyclic Compounds

Monoclonal Antibodies

Ocular Disease

69 patents: Sort by Forward Citations

1. 12753223 - Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis (2026-10-06),

2. 12624010 - Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway (2026-05-12),

3. 12600766 - Anti-TDP-43 Binding Molecules and Uses Thereof (2026-04-14),

4. 12552800 - Compounds for diagnosis (2026-02-17),

5. 12534519 - Novel Molecules for Therapy and Diagnosis (2026-01-27),

6. 12486319 - ANTI-TAU ANTIBODIES AND METHODS OF USE (2025-12-02),

7. 12324855 - Method of safe administration of phosphorylated Tau peptide vaccine (2025-06-10),

8. 12290553 - Method for vaccination against a self-antigen in a human patient (2025-05-06),

9. 12202840 - Compounds for the treatment or alleviation of disorders associated with Tau aggregates (2025-01-21),

10. 12005102 - Anti-abeta therapeutic vaccines (2024-06-11),

11. 11958889 - Compositions of phosphorylated tau peptides and uses thereof (2024-04-16),

12. 11814378 - Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates (2023-11-14),

13. 11684625 - Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates (2023-06-27),

14. 11684576 - Method of safe administration of phosphorylated tau peptide vaccine (2023-06-27),

15. 11623931 - Bicyclic compounds for diagnosis and therapy (2023-04-11),

Company Overview

AC Immune SA, based in Lausanne, Switzerland, is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly those associated with tau protein pathology. The company specializes in anti-tau antibodies and tau peptide vaccines, aiming to address conditions such as Alzheimer's disease through therapeutic vaccines and diagnostic compounds. AC Immune's research encompasses advanced technologies in humanized antibodies and phosphospecific antibodies, contributing to the understanding and treatment of neurofibrillary tangles.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

69 Patents

#8 in Lausanne

#226 in Switzerland

#10,784 in the World

Lausanne, Switzerland

Ac Immune Sa

Forward Citations = 307

70 inventors:

Andreas Muhs (33 out of 34 patents)

Andrea M Pfeifer (26 out of 36 patents)

Oskar Adolfsson (18 out of 18 patents)

4. Maria Pihlgren (17 out of 17 patents)

5. David T Hickman (13 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ac Immune Sa. Retrieved from https://idiyas.com/company/ac-immune-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…